The global anti-tuberculosis therapeutics market was valued at $1.34 billion in 2021 and it is expected to reach $2.9 billion at a CAGR of 7.2% between 2022 and 2032.Tuberculosis (TB) remains one of the most significant infectious diseases worldwide, posing a major global health challenge. Despite decades of efforts to control and eradicate the disease, TB continues to affect millions of people every year. However, advancements in anti-tuberculosis therapeutics offer hope in the battle against this persistent threat.
Browse the full report at @https://www.sheeranalyticsandinsights.com/market-report-research/anti-tuberculosis-therapeutics-market-21
Current Landscape of Tuberculosis:TB is caused by the bacterium Mycobacterium tuberculosis and primarily affects the lungs but can also affect other parts of the body. According to the World Health Organization (WHO), around 10 million people fell ill with TB in 2019, and approximately 1.4 million people died from the disease. The emergence of drug-resistant strains, particularly multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), further complicates treatment efforts.
Advancements in Therapeutics:In recent years, significant progress has been made in developing new anti-tuberculosis drugs and treatment regimens. These advancements have been driven by collaborative efforts between pharmaceutical companies, academic institutions, and global health organizations. Bedaquiline and delamanid are two notable examples of novel TB drugs approved by regulatory authorities in several countries.
Bedaquiline, developed by Janssen Pharmaceuticals, was approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of MDR-TB. It works by targeting the bacterial enzyme responsible for generating energy, thereby disrupting the bacterium's ability to replicate and survive. Delamanid, developed by Otsuka Pharmaceuticals, received approval in 2014 for the treatment of MDR-TB and is believed to inhibit the synthesis of mycolic acids, essential components of the bacterial cell wall.
In addition to these novel drugs, research efforts are focused on repurposing existing drugs and developing innovative treatment strategies. For example, the WHO recommends a combination therapy known as the "short-course regimen" for the treatment of drug-resistant TB. This regimen includes a combination of drugs such as bedaquiline, linezolid, and clofazimine and has shown promising results in clinical trials.
Challenges and Opportunities:Despite the progress made in anti-tuberculosis therapeutics, several challenges remain in the fight against TB. Access to these life-saving drugs remains a major barrier, particularly in low- and middle-income countries where TB burden is high. Issues such as high drug costs, limited healthcare infrastructure, and inadequate diagnostic capabilities hinder the effective implementation of TB treatment programs.
Furthermore, the emergence of drug-resistant TB strains underscores the need for continued research and development of new drugs and treatment regimens. Investment in TB research and development is crucial to address gaps in our understanding of the disease and to accelerate the development of new and more effective therapies.
Collaboration between governments, international organizations, and the private sector is essential to overcome these challenges and achieve the goal of ending the TB epidemic by 2030, as outlined in the United Nations Sustainable Development Goals. Increased funding for TB research, improved access to diagnostics and treatment, and strengthened healthcare systems are key priorities in this endeavor.
Get sample of this report @https://www.sheeranalyticsandinsights.com/request-sample/anti-tuberculosis-therapeutics-market-21
key players such as AstraZeneca (U.K), Abbvie (U.S), Cipla (India), Eli Lilly (U.S), Fresenius (Germany), Johnson and Johnson (U.S), Lupin (India), Lannett (U.S), Pfizer (U.S), Merck and Co. (U.S), Novartis (Switzerland), STI Pharma (U.S), Sanofi (France), Teva Pharmaceuticals (Israel), Viatris (U.S), among others
The Global Anti-Tuberculosis Therapeutics Market Has Been Segmented Into:
The Global Anti-Tuberculosis Therapeutics Market – by Disease Type:
Active TB
Latent TB
Others
The Global Anti-Tuberculosis Therapeutics Market – by Diagnosis Type:
Blood Tests
Sputum Tests
Imaging Tests
Others
The Global Anti-Tuberculosis Therapeutics Market – by Dosage Type:
Tablets and Capsules
Injections
Others
The Global Anti-Tuberculosis Therapeutics Market – Region Type:
North America
The U.S.
Canada
Mexico
Europe
U.K.
France
Germany
Italy
Rest of Europe
Asia Pacific
India
China
Japan
Australia
Rest of Asia Pacific
LAMEA
Middle East
Saudi Arabia
UAE
Others
Latin America
Brazil
Chile
Others
Africa
South Africa
Egypt
Others
About Us:
Sheer Analytics and Insights Private Limited is market research, consulting, and IT services company. We as a company believe in providing point to point data and its analysis with the combination of our human and automation integration. Sheer Analytics and Insights cover majorly eight industry verticals, including chemicals, life science, communications, and electronics, materials, consumer goods, defense, and BFSI sector.
Sheer Analytics believes in quality work and ensures that the product delivered to the client is meaningful for them. We publish reports based on our advanced analytics reports, which are generated with the help of our in-house databases, external databases, and artificial intelligence integration processes. We stand out from other market research companies in terms of integrating facts with meaningful insights for forecasting.
Contact:
Sheer Analytics and Insights
Call Us:- +1-414-240-5010
Comments